Osteosarcoma

Oncology
13
Pipeline Programs
12
Companies
14
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
3
6
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
343%
Peptide
229%
Monoclonal Antibody
229%
+ 7 programs with unclassified modality

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
2 programs
1
MifamurtidePhase 2Peptide1 trial
MifamurtideN/APeptide1 trial
Active Trials
NCT01194284Terminated25Est. Dec 2013
NCT02441309Terminated8Est. Nov 2016
Genentech
GenentechCA - Oceanside
2 programs
1
1
BevacizumabPhase 2Monoclonal Antibody1 trial
Surgical ResectionPhase 11 trial
Active Trials
NCT06492954Recruiting12Est. Jun 2027
NCT00667342Completed43Est. Aug 2017
Ipsen
IpsenChina - Tianjin
1 program
1
CabozantinibPhase 2Small Molecule1 trial
Active Trials
NCT06341712Active Not Recruiting10Est. Jun 2028
US WorldMeds
US WorldMedsKY - Louisville
1 program
1
EflornithinePhase 21 trial
Active Trials
NCT07321912Not Yet RecruitingEst. Apr 2036
E
EisaiChina - Liaoning
1 program
1
LenvatinibPhase 2Small Molecule1 trial
Active Trials
NCT04154189Completed81Est. Aug 2023
M&
Merck & Co.RAHWAY, NJ
1 program
1
robatumumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00617890Terminated219Est. Aug 2013
LP
Lee's PharmaceuticalChina - Guangzhou
1 program
1
ZKAB001 5mg/kgPhase 1/21 trial
Active Trials
NCT03676985Unknown15Est. Jun 2023
Zentalis Pharmaceuticals
1 program
1
ZN-c3Phase 1/21 trial
Active Trials
NCT04833582UnknownEst. Dec 2023
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
heavy ion radiotherapyPhase 1/21 trial
Active Trials
NCT01005043Completed23Est. Oct 2019
CT
1 program
1
1200mg of TQB2928 injection+AnlotinibPhase 1Small Molecule1 trial
Active Trials
NCT06438783TerminatedEst. Jun 2025
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
1
GlucarpidasePhase 11 trial
Active Trials
NCT03960177Active Not Recruiting12Est. Dec 2026
Umoja Biopharma
Umoja BiopharmaWA - Seattle
1 program
1
SCRI-E2CAR_EGFRtv1Phase 11 trial
Active Trials
NCT05312411Active Not RecruitingEst. May 2040

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
US WorldMedsEflornithine
IpsenCabozantinib
EisaiLenvatinib
TakedaMifamurtide
GenentechBevacizumab
Merck & Co.robatumumab
Zentalis PharmaceuticalsZN-c3
Lee's PharmaceuticalZKAB001 5mg/kg
Heidelberg Pharmaheavy ion radiotherapy
GenentechSurgical Resection
Chia Tai TianQing Pharmaceutical Group1200mg of TQB2928 injection+Anlotinib
Umoja BiopharmaSCRI-E2CAR_EGFRtv1
Knight TherapeuticsGlucarpidase
TakedaMifamurtide

Clinical Trials (14)

Total enrollment: 448 patients across 14 trials

NCT07321912US WorldMedsEflornithine

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Start: Apr 2026Est. completion: Apr 2036
Phase 2Not Yet Recruiting
NCT06341712IpsenCabozantinib

Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma

Start: Nov 2024Est. completion: Jun 202810 patients
Phase 2Active Not Recruiting
NCT04154189EisaiLenvatinib

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

Start: Mar 2020Est. completion: Aug 202381 patients
Phase 2Completed
NCT02441309TakedaMifamurtide

A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)

Start: Oct 2014Est. completion: Nov 20168 patients
Phase 2Terminated
NCT00667342GenentechBevacizumab

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

Start: Jun 2008Est. completion: Aug 201743 patients
Phase 2Completed
NCT00617890Merck & Co.robatumumab

A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)

Start: Feb 2008Est. completion: Aug 2013219 patients
Phase 2Terminated
NCT04833582Zentalis PharmaceuticalsZN-c3

A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma

Start: Aug 2021Est. completion: Dec 2023
Phase 1/2Unknown
NCT03676985Lee's PharmaceuticalZKAB001 5mg/kg

A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma

Start: Oct 2018Est. completion: Jun 202315 patients
Phase 1/2Unknown
NCT01005043Heidelberg Pharmaheavy ion radiotherapy

Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma

Start: Dec 2010Est. completion: Oct 201923 patients
Phase 1/2Completed
NCT06492954GenentechSurgical Resection

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

Start: Mar 2026Est. completion: Jun 202712 patients
Phase 1Recruiting
NCT06438783Chia Tai TianQing Pharmaceutical Group1200mg of TQB2928 injection+Anlotinib

TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors

Start: Feb 2024Est. completion: Jun 2025
Phase 1Terminated
NCT05312411Umoja BiopharmaSCRI-E2CAR_EGFRtv1

A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma

Start: May 2022Est. completion: May 2040
Phase 1Active Not Recruiting
NCT03960177Knight TherapeuticsGlucarpidase

Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

Start: Mar 2019Est. completion: Dec 202612 patients
Phase 1Active Not Recruiting
NCT01194284TakedaMifamurtide

Surveillance Study of Patients With Newly Diagnosed Osteosarcoma

Start: Dec 2011Est. completion: Dec 201325 patients
N/ATerminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
8m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
8m ago

Office Administrator

SystImmune
8m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
18m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
22m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
22m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 448 patients
12 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)